Healthcare policy and cost tracker: week of November 2, 2026
Three federal clocks strike inside one 60-day window. ACA marketplace open enrollment for 2027 opened November 1, 2026; December 15, 2026 is the deadline for coverage starting January 1; and January 1, 2027 is simultaneously the day Medicare’s negotiated drug prices take effect and the day prior-authorization APIs are due. The spine of this window: passivity — auto-renewal, missed deadlines, unappealed denials — is the expensive choice.
The Transparency in Coverage final rule (CMS-9882-F) and the October 23 Exchange-verification proposal were both covered in the October 26 edition.
The 60-day map
| Date | What happens | Who it hits |
|---|---|---|
| November 1, 2026 | 2027 ACA open enrollment opens in most states, running to January 15, 2027 (KFF) | Anyone buying their own coverage |
| December 15, 2026 | Deadline for coverage starting January 1, 2027 (healthinsurance.org) | Enrollees whose 2026 plan is terminating |
| January 1, 2027 | Medicare’s 15 negotiated Part D prices take effect; CMS-0057-F phase two FHIR APIs due (CMS fact sheet, CMS blog) | Part D enrollees; anyone in a plan subject to the rule |
| January 15, 2027 | Open enrollment closes in most states | Anyone still uninsured for 2027 |
| December 31, 2027 | The $50-per-month Medicare GLP-1 Bridge ends (Medicare.gov) | Bridge participants |
Cost to you: A missed December 15 pushes January 1 coverage to a qualifying life event. Do by December 15, 2026: Submit your 2027 application and confirm your first premium payment.
What the 2027 premiums actually do
The rate stack, in order: finalized average benchmark silver increase +13% for 2027, median proposed +15%, against +26% for 2025→2026 — a cumulative +42% across 2025 to 2027. HealthCare.gov states land at +11%; state-based marketplaces at +16%. Weighted average proposed increases run from under 7% in Vermont, Iowa and Utah to 29% in Arizona (KFF, healthinsurance.org). Insurers attributed about 4 percentage points of the 2026 increase to the expired enhanced credits and expect a similar additional effect in 2027.
The subsidy cliff is where the money sits. Enhanced premium tax credits expired at the end of 2025; about 22 million people received them in 2025, more than 90% of marketplace enrollees (CNBC). KFF estimated the lapse raises average subsidized payments 114% — from $888 a year to $1,904 a year. A single person earning $28,000 would pay nearly 6% of income ($1,562) instead of about 1% ($325) (KFF). Households above 400% of the federal poverty level qualify for no premium tax credit and pay full price.
Nothing is tracked this week on the legislative side: no vote, no bill, no pending measure on restoring the enhanced credits.
Cost to you: The average subsidized household moves from $888 to $1,904 a year. Do by December 15, 2026: Re-shop rather than renew — benchmark silver is not your only option.
Auto-renewal is the churn risk
As of October 29, 2026, 11 carriers announced exits from at least one state for 2027 and 7 announced entries into a new state. Cigna is leaving the individual market in all 11 states where it participates, and insurers are exiting marketplaces in more than 20 states — far more exits than entries (KFF, healthinsurance.org). Hundreds of thousands of enrollees have plans terminating at the end of 2026, and auto-renewal uses an algorithm to pick a replacement plan.
The demand side is already down: 2026 open enrollment plan selections fell 1.2 million; effectuated enrollment fell 12% (2.6 million) year over year to 19.2 million by February 2026; the wider individual market fell 18% by June 2026, from 25.2 million to 20.5 million. CBO projects marketplace enrollment falling from a peak of 22.4 million in 2025 to 13.1 million in 2027. Separately, 88% of marketplace growth since 2020 — 11.4 million of 12.9 million new enrollees — happened in states Trump won in 2024.
Cost to you: Auto-renewal can move you to a plan you did not choose, in a market with fewer carriers. Do by December 15, 2026: Check whether your carrier is in the exit list before you let the algorithm act.
State backfills, paused rules, and the enrollment cleanup
Five states are backfilling federal help: New Mexico fully replaced the lost federal assistance in 2026 and continues it in 2027; California expanded state help to households at 165%–200% of the federal poverty level, previously 138%–165%; New Jersey maintains its program; Rhode Island and Virginia created new state subsidies for 2027 (KFF).
Litigation has paused or vacated five 2027 provisions: income verification, network adequacy, elimination of standardized plans, the gender-affirming-care essential-health-benefit rule, and the rule that would have shortened open enrollment to nine weeks. Catastrophic plans remain limited to people under 30, people whose coverage would cost more than 8.5% of income, and hardship exemptions.
The enrollment file is also being cleaned: in September 2026 HHS reported cancelling coverage for about 760,000 “phantom” enrollees and sent insurers a list of about 1.2 million people to review. That is a reason to confirm your own record is real — and paid.
Cost to you: A record flagged as phantom means no coverage on January 1. Do by December 15, 2026: Log in, verify your application, your plan, and that payment posted.
Medicare’s negotiated prices, January 1, 2027
Fifteen Part D drugs carry maximum fair prices effective January 1, 2027; with the first cycle’s 10, 25 drugs are negotiated. Discounts off the 2024 list price run 38% to 85%. A “38% to 79%” figure is circulating — it is wrong; the CMS fact sheet’s range is 38% to 85% (CMS fact sheet).
Table 3 — 2027 negotiated price vs. 2024 list price, 30-day supply
| Drug | 2024 list price | 2027 negotiated price | Discount |
|---|---|---|---|
| Ozempic / Rybelsus / Wegovy | $959 | $274 | 71% |
| Trelegy Ellipta | $654 | $175 | 73% |
| Xtandi | $13,480 | $7,004 | 48% |
| Pomalyst | $21,744 | $8,650 | 60% |
| Ofev | $12,622 | $6,350 | 50% |
| Ibrance | $15,741 | $7,871 | 50% |
| Linzess | $539 | $136 | 75% |
| Calquence | $14,228 | $8,600 | 40% |
| Austedo / Austedo XR | $6,623 | $4,093 | 38% |
| Breo Ellipta | $397 | $67 | 83% |
| Xifaxan | $2,696 | $1,000 | 63% |
| Vraylar | $1,376 | $770 | 44% |
| Tradjenta | $488 | $78 | 84% |
| Janumet / Janumet XR | $526 | $80 | 85% |
| Otezla / Otezla XR | $4,722 | $1,650 | 65% |
Program math: these 15 drugs accounted for $42.5 billion in 2024 gross Part D costs (about 15% of the program); 5.3 million Part D enrollees used them; beneficiary out-of-pocket spending on them was $1.7 billion. CMS estimates $12 billion in net savings (44%) had the prices applied in 2024, or about $8.5 billion (36%) including the Coverage Gap Discount Program, with projected 2027 beneficiary out-of-pocket savings of $685 million. Eight of the 15 deals were reached in meetings or price exchanges; for the other seven, companies accepted CMS’s written final offer. The negotiation period ended November 1, 2025.
Whether these prices move private, employer, exchange or cash prices is unknown — nothing in this record establishes spillover.
Cost to you: If you take one of these 15 drugs under Part D, the negotiated price replaces the old price on January 1. Do by January 1, 2027: Confirm your plan’s formulary lists the drug at the negotiated tier.
The $50 GLP-1 bridge and its two clocks
The Medicare GLP-1 Bridge pays $50 per month from July 1, 2026 through December 31, 2027, nationwide, for people with Medicare Part D (Medicare.gov, CMS release). Covered products: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound KwikPen only — single-dose Zepbound vials and pens are not covered.
As written by Medicare, eligibility is age 18+ with: BMI 35 or higher; or BMI 30 or higher plus diastolic heart failure (HFpEF), uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher; or BMI 27 or higher plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Not eligible: anyone already getting a GLP-1 through their Part D plan, or who has type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease — their plan may still cover a GLP-1 separately. These are Medicare’s program rules, not medical guidance.
The prescriber must certify the drug is used as part of a diet-and-exercise lifestyle program and must complete prior authorization when asked; the authorization stays valid through December 31, 2027, including refills and dose changes, unless the drug changes.
The $50 copay fine print, all five points: it does not count toward the Part D deductible; it does not count toward the annual out-of-pocket limit; it does not appear on the Part D explanation of benefits or the Medicare Summary Notice; it cannot be lowered by Extra Help; and it cannot be spread across months through the Medicare Prescription Payment Plan.
The two clocks in one place: the semaglutide negotiated price of $274 per 30-day supply starts January 1, 2027, and the $50 bridge ends December 31, 2027. After the bridge ends, ordinary Part D cost sharing applies to the negotiated price. No 2028 figure exists in the record.
Cost to you: The $50 copay is invisible on your statements — track it yourself or you will not see it. Do by December 31, 2027: Confirm prior authorization is on file before the bridge closes.
Hospital price transparency files get harder to fake
The CY 2026 hospital outpatient/ASC final rule (CMS-1834-FC) rewrites the machine-readable file (CMS fact sheet): it replaces the estimated allowed amount with the median allowed amount and adds 10th and 90th percentile allowed amounts in dollars; it adds a count of the allowed amounts used for those three statistics; the numbers must come from EDI 835 electronic remittance advice or an equivalent remittance source, with the next highest observed value used where a computed value falls between two observed amounts and a lookback of at least 12 and no more than 15 months; it requires an attestation under 45 CFR 180.50 that the file is true, accurate and complete, carrying the name of the hospital’s CEO, president or designated senior official; and it requires Type 2 organizational NPIs with taxonomy codes beginning 27 or 28.
Enforcement runs through CMS audits of a sample of hospitals and investigations of complaints, then a corrective action plan, then civil monetary penalties; consumers can file a complaint with CMS (CMS enforcement actions, CMS data). Secondary-source data — a secondary aggregation of CMS penalty notices (CoveredUSA) — shows maximum penalties of $300 a day for hospitals of 30 beds or fewer, $10 per bed per day for 31–550 beds, and $5,500 a day above 550 beds; a 35% penalty reduction available from January 1, 2026 to hospitals that waive a formal hearing within 30 days (usage is unknown); 27 hospitals fined since June 2022; more than $5 million in penalties; 10 fines in 2025; and a largest single penalty of $979,000 at UF Health North in Jacksonville, Florida. No compliance percentage exists in this record.
Cost to you: A file you cannot read is a price you cannot challenge. Do by January 1, 2027: Pull your hospital’s machine-readable file and file a CMS complaint if it is missing or unreadable.
Prior authorization: what changed in October 2026
UnitedHealthcare eliminated prior authorization for roughly 1,700 medical codes starting October 2026 — about 30% of its preapproval requirements: more than 800 commercial codes, about 940 ACA codes, about 120 Medicare Advantage and dual-eligible codes, with Oxford plans removing 1,400 codes. Categories include oncology, cardiology, orthopedics and musculoskeletal procedures, genetic and lab testing, chiropractic care, physical/occupational/speech therapy, home health and durable medical equipment. No state-by-state breakdown is published (Healthcare Dive).
CMS-0057-F runs in two phases: phase one took effect January 1, 2026 — decisions within 72 hours for urgent and seven calendar days for standard requests, specific reasons for every denial, public metrics by March 31 — and phase two is due January 1, 2027, FHIR-based APIs to automate the process end to end (CMS blog). The rule does not apply to commercial fully insured plans or ERISA self-insured employer plans.
Table 5 — first-year public denial and overturn data (KFF, August 13, 2026)
| Plan type | Standard requests denied | Overturned on appeal | Median response |
|---|---|---|---|
| Medicare Advantage | 12% | 67% | ~1 day standard; ~half a day expedited |
| Medicaid managed care | 14% | 47% | ~1 day standard |
| ACA marketplace | 18% | 43% | ~1 day standard |
Denials are rarely appealed — which is the expensive habit. Provider-side data: MGMA’s September 2026 poll found 44% of medical group leaders said turnaround got slower in 2026 than 2025, and its 2026 Regulatory Burden Report found 90% of practices reported more burden over the prior 12 months. CMS says completing authorizations costs providers $20–50 an hour and 13 hours a week — nearly $34,000 and 700 hours a year per provider; it cites an 11% reduction in requirements (6.5 million fewer authorizations) and estimates $15 billion in savings over 10 years (Insurance Business, KFF).
Cost to you: In ACA marketplace plans, 18% of standard requests were denied — and 43% of those denials were overturned on appeal. Do by January 1, 2027: Appeal in writing; ask for the specific denial reason the rule now requires.
Your dated action calendar
| Date | Action |
|---|---|
| November 2, 2026 | Log in; verify application, plan, and that payment posted |
| November 9, 2026 | Check carrier exits; confirm your plan still exists for 2027 |
| November 30, 2026 | Compare benchmark silver against at least two alternatives |
| December 15, 2026 | Submit 2027 application; deadline for January 1 coverage |
| January 1, 2027 | Confirm negotiated Part D price; check FHIR API availability |
| January 15, 2027 | Open enrollment closes in most states |
FAQ
1. Does the December 15 deadline apply to me if my state runs its own marketplace? December 15 is the deadline for coverage starting January 1, 2027; open enrollment in most states runs through January 15, 2027. Check your state’s exact dates when you apply.
2. Will auto-renewal keep my current plan? Not necessarily. With 11 carrier exits and 7 entries as of October 29, 2026, and hundreds of thousands of plans terminating, auto-renewal uses an algorithm to pick a replacement.
3. What if I earn above 400% of the federal poverty level? You qualify for no premium tax credit and pay full price.
4. Which drugs are negotiated on January 1, 2027? Fifteen Part D drugs, listed in Table 3 above, with discounts from 38% to 85% off 2024 list prices.
5. Am I eligible for the $50 GLP-1 Bridge? Eligibility is set by Medicare’s program rules on Medicare.gov. This tracker does not give medical advice.
6. Does the CMS-0057-F API deadline help my employer plan? No. The rule does not apply to commercial fully insured plans or ERISA self-insured employer plans.
7. Can I see what a hospital charges before I go? Yes — the CY 2026 final rule requires median, 10th and 90th percentile allowed amounts in dollars plus a count, sourced from EDI 835 remittance data. If the file is missing, file a complaint with CMS.
Cost to you: An unanswered FAQ question on December 14 becomes a coverage gap on January 1. Do by December 15, 2026: Ask your insurer directly and keep the written reply.
The Bottom Line
Three clocks, one verdict. The 2027 marketplace is more expensive (+13% finalized average, +42% cumulative since 2025) and thinner (11 exits vs. 7 entries, Cigna gone from all 11 of its states). Medicare’s negotiated prices are real and dated January 1, 2027 — 38% to 85% off 2024 list prices across 15 drugs — but they do not touch private or cash prices, which remains unknown. Prior authorization got looser at UnitedHealthcare and stricter at the API layer. In every one of those, the passive choice costs more than the active one: auto-renewal picks for you, an unappealed denial stands at 43%–67% overturn rates, and a missed December 15 closes January 1.
Cost to you: Passivity is the premium you pay for not opening the portal. Do by December 15, 2026: Shop, verify, and confirm payment.
How this guide was built
Figures come from CMS, KFF, Medicare.gov, CNBC, healthinsurance.org, Healthcare Dive and Insurance Business pages fetched on November 2, 2026, plus the CoveredUSA secondary aggregation of CMS penalty notices and the CMS enforcement and data pages. Penalty totals are labeled secondary-source throughout. No hands-on testing applies: this is a policy-and-price roundup, not a product review, so there is no lab, no account signup and no plan-quote run behind it. Where the record does not establish something — a compliance rate, a 2027 Part D premium, a 2028 GLP-1 figure, a state-by-state breakdown of UnitedHealthcare’s code cuts, a spillover effect on private prices, or any legislative action on the enhanced credits — this post says so instead of filling the gap. No clinical advice is given anywhere in this tracker.